Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study
Authors:
- Masaya MorimotoMMMasaya Morimoto
- Yuma YokoyaYYYuma Yokoya
- Kikuaki YoshidaKYKikuaki Yoshida
- Hideki KosakoHKHideki Kosako
- Yoshikazu HoriYHYoshikazu Hori
- Toshiki MushinoTMToshiki Mushino
- Shinobu TamuraSTShinobu Tamura
- Reiko ItoRIReiko Ito
- Ryosuke KoyamadaRKRyosuke Koyamada
- Takuya YamashitaTYTakuya Yamashita
- Shinichiro MoriSMShinichiro Mori
- Nobuyoshi MoriNMNobuyoshi Mori
Open Access
- 7 February 2024
- journal article
- research article
- Published by MDPI AG in Hematology Reports
- Vol. 16 (1) , 76-88
Abstract
Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for a positive hepatitis panel, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic reviewCritical Reviews in Oncology/Hematology, 2014
- Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical managementJournal of Hepatology, 2013
- Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimensAnnals of Hematology, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia studySupportive Care in Cancer, 2008
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancerCancer, 2004
- Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphomaCancer, 2003
- Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategyJournal of Clinical Epidemiology, 1995
- Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimatesJournal of Clinical Epidemiology, 1995